Xerostomia Clinical Trial
Official title:
Finger-prick Autologous Blood (FAB) for Use in Dry Mouth
This is a feasibility study that will assess the efficacy of using autologous blood to treat
moderate to severe dry mouth. Dry mouth has been estimated to affect up to 64.8% of the
general population (Navazesh et al., 2009) and many patients that are affected by Sjögren's
syndrome or have had radiation therapy to combat head or neck cancer (Navazesh et al., 2009).
The blood will be applied to the interior of the mouth by means of a mouthwash. This research
poses the first potential curative treatment for dry mouth - all other current dry mouth
treatments are either symptomatic or lifestyle-based.
Autologous blood has been shown to be effective in treating the epithelial surface of dry
eyes. This has been attributed to the analogous growth factors in the blood to that of tears
- and potentially in this case, saliva - in healing the oral epithelial surface (Herbst et
al., 2004).
Fingerprick autologous blood (FAB) has been demonstrated to be effective in treating dry eye
disease by inducing healing of the epithelial surface of the eye (Than et al., 2017). The
epithelial layers of both the mouth and the eye require a non-vascular source of lubrication
and nutrients (tears and saliva respectively). These nutrients include growth factors -
naturally occurring substances capable of stimulating cellular growth. Saliva provides
transforming growth factor alpha (TGF - α) (Mogi et al., 1995), epidermal growth factor (EGF)
(Herbst, 2004; Marti et al., 1989), and Hepatocyte growth factor (HGF) (Amano et al., 1994)
whilst tears provide EGF (Ohashi et al., 1989) amongst others (including TGF -β 1 and 2
(Gupta et al., 1996) integral to the proliferation, survival and differentiation of the oral
epithelial cells (Klenkler et al., 2007). Therefore, as severe dry mouth disease (and a
subsequent lack of saliva and growth factors) causes damage to the epithelial surface lining
the mouth, a growth factor rich saliva substitute like FAB, should be an effective treatment
for dry mouth. There is currently no study which details FAB for use in dry mouth.
Whole or parts of the three major salivary glands have been surgically transplanted or
redirected to provide a replacement tear film in patients with severe dry eyes. This has been
shown to be successful in both lubricating and improving eye comfort in afflicted patients
(Geerling & Sieg, 2008). Since both blood and saliva have been shown to be effective as tear
substitutes, it stands to reason that both tears and blood may be effective as a saliva
substitute. Both tears and saliva are extraordinarily complex blood derived biological
products which provide nourishment to an epithelial surface, and as such, blood should serve
as a sufficiently close mimic of saliva.
Sjögren's syndrome, a chronic systemic autoimmune disease, occurs due to infiltration of
secretory (exocrine) glands including the eye and mouth, resulting in dry eye and mouth
respectively. FAB has been shown to be effective in treating Sjögren's induced dry eye and
logically should also be an efficacious treatment for Sjögren's induced dry mouth.
Currently no curative measures for dry mouth exist. Oral dryness is managed conservatively by
providing lubrication through a temporary solution such as lifestyle changes, artificial
sprays, dry mouth mouthwash solutions or sialagogues (Shirlaw & Khan, 2017). There is no
treatment that addresses the complexity of salivary constituents. Oral pilocarpine can be
used to stimulate salivary glands at least as effectively as artificial saliva, however side
effects were high including sweating, urinary frequency and vasodilation (Davies & Thompson,
2015).
Thus, FAB offers a potentially novel and better way than currently prescribed methods to
treat dry mouth disease.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05342272 -
Comparison of Gum® HydralTM Moisturizing Gel and Biotene® Oral Gel in Dry Mouth Sensation Reduction
|
Phase 3 | |
Completed |
NCT03302676 -
The Use of Chewing Gum for Xerostomia and Hyposalivation After Radiotherapy for Oral and Oropharyngeal Tumors
|
N/A | |
Completed |
NCT02375451 -
Effect of Childhood Radioiodine Therapy on Salivary Function
|
N/A | |
Completed |
NCT01272570 -
Oral Health and Oral Health-Related Quality of Life in Early Stage Breast Cancer Survivors
|
N/A | |
Completed |
NCT00656513 -
Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer
|
Phase 2/Phase 3 | |
Completed |
NCT00911768 -
Effect of Korean Red Ginseng (KRG) on Dry Mouth
|
Phase 4 | |
Completed |
NCT00332618 -
Efficacy Study of Oxygenated Glycerol Triesters to Treat Xerostomia
|
Phase 2 | |
Completed |
NCT03494985 -
A Clinical Study to Evaluate the Efficacy of Three Dry Mouth Relief Products Versus Water
|
N/A | |
Completed |
NCT05058430 -
SaliPen Human Factors Study for OTC Labeling
|
N/A | |
Recruiting |
NCT02705937 -
Early Phase Study Comparing the Effectiveness of a Dairy Product With the Reference Treatment Aequasyal® on Dry Mouth Symptoms in Patients Suffering From Xerostomia Caused by Psychotropic Medications.
|
N/A | |
Completed |
NCT05247008 -
Effectiveness of Thyme Honey in Management of Xerostomia in ESRD
|
N/A | |
Recruiting |
NCT03632096 -
Photobiomodulation in Salivary Production of Patients With Xerostomy
|
Phase 2 | |
Not yet recruiting |
NCT04323384 -
The Effect of Biotene® on the Symptoms of Xerostomia and Mastication and Swallowing
|
N/A | |
Active, not recruiting |
NCT03176368 -
Coconut Oil: Managing Radiation-Induced Xerostomia
|
N/A | |
Enrolling by invitation |
NCT06122636 -
Efficacy of a Probiotic and Microbiological Analysis on Oral Complications Induced by Antineoplastic Therapies in Patients With HNC
|
N/A | |
Completed |
NCT03611283 -
Topical Management of Xerostomia With Dry Mouth Products
|
N/A | |
Completed |
NCT02682199 -
Prospective Evaluation of Patient Reported Xerostomia After Whole Brain Radiation
|
||
Withdrawn |
NCT01960101 -
Development of a Milk Product Substitution for Patients Suffering From Xerostomia Caused by Medication
|
N/A | |
Completed |
NCT02317172 -
Efficacy of Novel Edible Gel-based Artificial Saliva in Thai Geriatric Populations With Systemic Diseases
|
N/A | |
Completed |
NCT00350350 -
OGT Spray in the Management of Xerostomia in the Elderly
|
Phase 3 |